Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00778973 · ClinicalTrials.gov registry record · NA

Bioequivalence Study of Sertraline Hydrochloride 100mg Tablets Under Fed Conditions

A NA study of Healthy, sponsored by Ranbaxy Laboratories Limited.

Completed
Registry status
NA
Development phase
36
Enrollment target
1
Study location

NCT00778973: Completed NA study of Healthy, sponsored by Ranbaxy Laboratories Limited.

NCT00778973 is a NA study of Healthy that has completed, run by Ranbaxy Laboratories Limited. The registered enrollment target is 36 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00778973, a NA study of Healthy, has completed, sponsored by Ranbaxy Laboratories Limited.

COMPLETED
Registry status
NA
Development phase
36 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study was to evaluate the relative bioavailability of the test formulation of sertraline 100 mg tablets with an already marketed reference formulation Zoloft® 100 mg tablets (Pfizer), under non-fasting conditions in healthy male and female adult subjects.

Conditions Studied

Interventions

  • DRUG sertraline 100 mg tablets

Study Locations (1)

Pennsylvania

  • Novum Pharmaceutical Research Services - Pittsburgh

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2005-08
Est. Completion 2005-10
Phase NA
Ranbaxy Laboratories Limited

44 total trials

What the finished NCT00778973 record still lists

NCT00778973 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (94% lower).

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which sertraline 100 mg tablets is the first listed.

NCT00778973 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT00778973 about?

NCT00778973 is a clinical study titled "Bioequivalence Study of Sertraline Hydrochloride 100mg Tablets Under Fed Conditions". The purpose of this study was to evaluate the relative bioavailability of the test formulation of sertraline 100 mg tablets with an already marketed reference formulation Zoloft® 100 mg tablets (Pfizer), under non-fasting conditions in healthy male and female adult subjects.

What is the current status of trial NCT00778973?

This trial is currently completed. It is a NA study. The enrollment target is 36 participants. The study started on 2005-08. Estimated completion is 2005-10.

What conditions does trial NCT00778973 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT00778973?

The interventions under investigation include: sertraline 100 mg tablets (DRUG).

Who is sponsoring clinical trial NCT00778973?

This trial is sponsored by Ranbaxy Laboratories Limited, which has 44 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00778973 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00778973's enrollment target sits among peer trials

36 595th of 1090 higher than 469 of 1,090 other Healthy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00929006 · 36 participants · Early Phase 1

    Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism

  • NCT01891318 · 36 participants · Phase 1

    Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study

  • NCT02291848 · 36 participants · Phase 1

    Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma

  • NCT02366819 · 36 participants · Phase 4

    Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00778973, the US trial registry maintained by the National Library of Medicine. NCT00778973 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.